McKenzie Colin, Sloot Bart, Amorim Felippe Espinelli, Robbins Trevor W, Milton Amy L
Department of Psychology, University of Cambridge, Downing Site, Cambridge, CB2 3EB, UK.
University of Radboud, Nijmegen, The Netherlands.
Psychopharmacology (Berl). 2025 Apr 3. doi: 10.1007/s00213-025-06774-2.
Obsessive-compulsive disorder (OCD) affects 1-3% of the population. Current therapies, including selective serotonin reuptake inhibitors, are not universally effective in managing OCD. Recent discoveries indicating hyperactivation of key regions within the corticostriatal thalamic circuitry that supports OCD, and alterations in the ratio of glutamate: GABA in regions such as the anterior cingulate cortex, suggest that drugs targeting glutamatergic signalling may be effective in reducing OCD symptoms.
This study sought to determine whether two drugs targeting metabotropic glutamate receptors could reduce excessive checking behaviour in a rodent analogue of compulsive-like checking in OCD, the Observing Response Task (ORT).
Rats were trained on the ORT and separately classified on a pavlovian autoshaping task to identify the subpopulation of sign-trackers, which show higher levels of excessive checking. Once responding had stabilised, rats received systemic administration of different doses of the mGluR2 positive allosteric modulator AZD-8529 and its vehicle in a Latin square design, and the effects on ORT performance were assessed. Following completion of AZD-8529 dosing, a subset of rats received administration of different doses of the mGluR2/3 agonist LY404039 and its vehicle in a Latin square design, and ORT performance assessed.
Both AZD-8529 and LY404039 produced dose-dependent reductions in checking behaviour, including at doses that did not impair generalised measures of task performance.
The similarity in effect of AZD-8529 and LY404039 suggests that the capacity of these drugs to reduce checking is mediated by mGluR2s, which may provide a promising target for future treatment development for OCD.
强迫症(OCD)影响着1%至3%的人口。目前的治疗方法,包括选择性5-羟色胺再摄取抑制剂,在治疗强迫症方面并非普遍有效。最近的研究发现表明,支持强迫症的皮质纹状体丘脑回路中的关键区域过度活跃,以及前扣带回皮质等区域谷氨酸与γ-氨基丁酸比例的改变,这表明针对谷氨酸能信号传导的药物可能有效减轻强迫症症状。
本研究旨在确定两种靶向代谢型谷氨酸受体的药物是否能减少强迫症中强迫性检查行为的啮齿动物类似行为,即观察反应任务(ORT)中的过度检查行为。
对大鼠进行ORT训练,并在巴甫洛夫自动形成任务中分别进行分类,以识别表现出更高水平过度检查行为的标志追踪者亚群。一旦反应稳定,大鼠在拉丁方设计中接受不同剂量的代谢型谷氨酸受体2(mGluR2)正性变构调节剂AZD - 8529及其赋形剂的全身给药,并评估对ORT表现的影响。在完成AZD - 8529给药后,一部分大鼠在拉丁方设计中接受不同剂量的mGluR2/3激动剂LY404039及其赋形剂的给药,并评估ORT表现。
AZD - 8529和LY404039均产生了剂量依赖性的检查行为减少,包括在不损害任务表现总体测量的剂量下。
AZD - 8529和LY404039效果的相似性表明,这些药物减少检查行为的能力是由mGluR2介导的,这可能为未来强迫症治疗的发展提供一个有前景的靶点。